Relationship between dietary inflammatory index and metabolic dysfunction associated steatotic liver disease in children

被引:0
|
作者
Amiri, Fateme [1 ]
Moludi, Jalal [1 ]
Jouybari, Touraj Ahmadi [2 ]
Qasemi, Mahmoud [3 ]
Sharifi, Maryam [1 ]
Mahaki, Behzad [4 ]
Soleimani, Davood [1 ]
机构
[1] Kermanshah Univ Med Sci, Sch Nutr Sci & Food Technol, Dept Nutr Sci, Kermanshah, Iran
[2] Kermanshah Univ Med Sci, Imam Khomeini & Mohammad Kermanshahi & Farabi Hosp, Clin Res Dev Ctr, Kermanshah, Iran
[3] Kermanshah Univ Med Sci, Sch Med, Dept Pediat, Kermanshah, Iran
[4] Kermanshah Univ Med Sci, Sch Hlth, Dept Biostat, Kermanshah, Iran
来源
SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期
关键词
Non-alcoholic fatty liver disease; Fibrosis; Diet; Inflammation; Pediatrics; NONALCOHOLIC FATTY LIVER; METAANALYSIS; NUTRIENTS; PATTERN; RISK;
D O I
10.1038/s41598-025-89690-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Emerging research suggests a connection between dietary habits and metabolic dysfunction associated steatotic liver disease (MASLD). We aimed to assess the relationship between the Dietary Inflammatory Index (DII) and the severity of MASLD. This cross-sectional study involved 125 participants aged 7-18 with MASLD. Dietary intakes were assessed using a validated 147-item food frequency questionnaire. The DII was applied to measure diet-induced inflammation, categorizing diets into anti-inflammatory (DII < -1) and inflammatory diets (DII > + 1). To evaluate hepatic steatosis and fibrosis, transabdominal ultrasonography and the fibrosis-4 (FIB-4) index were utilized. After adjusting for potential confounding factors, individuals on inflammatory diets exhibited a significantly higher odds ratio (OR) for experiencing more severe steatosis (OR: 4.11; 95% CI: 1.08-15.71) compared to those on anti-inflammatory diets. Furthermore, each unit increase in DII scores was linked to a 2.6-fold increase in the odds of more severe steatosis (OR: 2.61; 95% CI: 1.28-5.32) and a 0.006 increase in FIB-4 scores (beta: 0.006; 95% CI: 0.003-0.011). In conclusion, modifying dietary intakes to lower DII scores may be a beneficial approach to improving clinical outcomes in pediatric MASLD, as anti-inflammatory diets are associated with reduced severity of hepatic steatosis and fibrosis.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [22] Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update
    Sookoian, Silvia
    Rotman, Yaron
    Valenti, Luca
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (11) : 2177 - 2187
  • [23] Beyond Nonalcoholic Fatty Liver Disease: The Expansive Realm of Metabolic Dysfunction-associated Steatotic Liver Disease
    Samadarshi, Samir
    Kumar, Dharmendra
    Manrai, Manish
    Dawra, Saurabh
    Srivastava, Sharad
    Chandra, Alok
    JOURNAL OF MARINE MEDICAL SOCIETY, 2025, 27 (01) : 54 - 58
  • [24] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)
  • [25] Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center
    dos Remedios Pamplona de Oliveira, Livia
    da Rocha Ribeiro, Tarsila Campanha
    Mourao-Junior, Carlos Alberto
    de Lima Barra, Maria Antonia
    Silva, Mariana Hippert Gonsalves
    Shafee, Luis Pordeus
    Zacarias, Sarah Mendes
    da Costa Campos, Lenilton
    Valerio, Helena Maria Giordano
    Chebli, Julio Maria Fonseca
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2024, 70 (06):
  • [26] Therapeutic management of metabolic dysfunction associated steatotic liver disease
    Zeng, Jing
    Fan, Jian-Gao
    Francque, Sven M.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, 12 (02) : 177 - 186
  • [27] Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
    Stefan, Norbert
    Roden, Michael
    DIABETOLOGIE UND STOFFWECHSEL, 2024, 19 : S290 - S296
  • [28] Retinopathy in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Orfanidou, Myrsini
    Polyzos, Stergios A.
    MEDICINA-LITHUANIA, 2025, 61 (01):
  • [29] The liver-brain axis in metabolic dysfunction-associated steatotic liver disease
    Mikkelsen, Anne Catrine Daugaard
    Kjaergaard, Kristoffer
    Schapira, Anthony H. V.
    Mookerjee, Rajeshwar P.
    Thomsen, Karen Louise
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (03): : 248 - 258
  • [30] Frontiers of Collaboration between Primary Care and Specialists in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review
    Nagai, Koki
    Nagai, Kazuki
    Iwaki, Michihiro
    Kobayashi, Takashi
    Nogami, Asako
    Oka, Masanao
    Saito, Satoru
    Yoneda, Masato
    LIFE-BASEL, 2023, 13 (11):